Nasri Elahe, Fakhim Hamed, Salahi Mehrdad, Ghafel Safiyeh, Pourajam Samane, Darakhshandeh Ali, Kassaian Nazila, Sadeghi Somayeh, Ataei Behrooz, Javanmard Shaghayegh Haghjooy, Vaezi Afsane
Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Adv Biomed Res. 2023 Jan 27;12:3. doi: 10.4103/abr.abr_104_21. eCollection 2023.
Prophylaxis could be an established strategy to potentially prevent and control infectious diseases and should be considered in the coronavirus disease 2019 (COVID-19) pandemic. The present study aimed to assess the effectiveness of hydroxychloroquine as a prophylaxis treatment strategy in the reduction of the risk of COVID-19 among health professionals.
The health professionals were randomly assigned (1:1) to the control group without receiving any hydroxychloroquine as prophylaxis and the hydroxychloroquine group receiving a weekly hydroxychloroquine dose of 400 mg up to 12 weeks.
A total of 146 health professionals were randomly enrolled in this study between August 11 and November 11 in 2020. Among the screened health professionals, 21 (14.6%) were infected with COVID-19 during the 12 weeks, and 14 (66.6%) out of the 21 health professionals were in the control group. Most participants with COVID-19 had mild symptoms (62%). In addition, 9.5% ( = 2) of the participants suffered from moderate disease and 28.5% were diagnosed with severe symptoms. In the hydroxychloroquine group, 5 (7.1%) and 2 (2.8%) participants were reported with mild and moderate symptoms of COVID-19, respectively, and 2 participants had moderate, 8 (10.9%) participants had mild symptoms, and 6 (8.2%) participants had severe symptoms in the control group, within 3 months. Severe symptoms of COVID-19 were not observed in the hydroxychloroquine group.
This study addressed the effect and benefit of hydroxychloroquine administration for the prevention of COVID-19 among health professionals. The improved perception of prophylaxis might highlight its important role in future COVID-19 outbreaks to prevent hospital transmission, which is a major route of spread.
预防可能是一种既定策略,可潜在地预防和控制传染病,在2019冠状病毒病(COVID-19)大流行中应予以考虑。本研究旨在评估羟氯喹作为一种预防治疗策略在降低医护人员感染COVID-19风险方面的有效性。
医护人员被随机分配(1:1)至未接受任何羟氯喹预防的对照组和接受每周400毫克羟氯喹剂量、持续12周的羟氯喹组。
2020年8月11日至11月11日期间,共有146名医护人员被随机纳入本研究。在筛查的医护人员中,21人(14.6%)在12周内感染了COVID-19,其中21名感染医护人员中有14人(66.6%)在对照组。大多数感染COVID-19的参与者症状较轻(62%)。此外,9.5%(=2)的参与者患有中度疾病,28.5%被诊断为重症。在羟氯喹组中,分别有5名(7.1%)和2名(2.8%)参与者报告有COVID-19的轻度和中度症状,在对照组中,3个月内有2名参与者患有中度症状,8名(10.9%)参与者有轻度症状,6名(8.2%)参与者有重症症状。羟氯喹组未观察到COVID-19的重症症状。
本研究探讨了羟氯喹给药对医护人员预防COVID-19的效果和益处。对预防的更好认识可能会凸显其在未来COVID-19疫情中预防医院传播的重要作用,而医院传播是主要传播途径。